New Study Suggests FebriDx® as a ‘Front Door Triage Tool’ in the Fight Against COVID-19

A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled “Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19” identifies the FebriDx® test as a rapid, highly accurate, and affordable ‘front door triage tool’ to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19. In this study of 251 patients, FebriDx showed high diagnostic accuracy and speed for identifying a viral infection when compared to PCR for confirming COVID-19.

SEE ALSO
June 21, 2022

Lumos Diagnostics Appoints Doug Ward As CEO

Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance.

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.